NCT05564377 2026-04-16
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
7 trialsNCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
NCT05554328 2026-04-13
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04065269 2026-02-20
ATARI
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
NCT03745950 2024-12-04
UTOLA
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT03570437 2022-03-02
COPELIA
University of Manchester
Phase 2 Unknown
NCT03951415 2021-04-01
DOMEC
Leiden University Medical Center
Phase 2 Unknown